Biosensor, procedure for obtaining said biosensor, method for the detection of Pseudomonas aeruginosa, and detection kit using said sensor for the rapid detection of P. aeruginosa

Patent number:

P202430694

Comunidad Valenciana.svg
No items found.

Pseudomonas aeruginosa is a gram-negative opportunistic pathogen that is particularly problematic in Intensive Care Units and ranks among the most significant causes of hospital-associated bacterial infections. Its broad and potent pathogenic profile, along with its ability to exhibit multidrug resistance, enables it to cause acute infections that often become chronic, making it associated with high morbidity and mortality in many groups of immunocompromised patients. Due to its ease of transmission, the large number of multidrug-resistant strains, and the long and complex diagnostic times, a new system has been developed to detect Pseudomonas aeruginosa in clinical patient samples in less than 30 minutes. The presented invention enables the semi-quantitative detection of Pseudomonas aeruginosa DNA through the implementation of molecular gates on hybrid porous organic-inorganic supports that specifically and selectively recognize bacterial DNA. In this system, the designed oligonucleotides acting as molecular gates, which block the pores of the support, are capable of detaching from the surface only in the presence of the analyte, thereby enabling the release of a fluorogenic indicator previously introduced into the porous interior. Monitoring the signal resulting from the release of the fluorogenic indicator by the developed biosensor has demonstrated its ability to distinguish, in less than 30 minutes, between clinical samples from healthy patients and those infected with Pseudomonas aeruginosa, with a low detection limit between 9.8 × 10⁻² and 10 CFU mL⁻¹ and high specificity against other species of the Pseudomonas genus. This new system allows for the detection of bacterial DNA even at the early stages of infection, thereby helping physicians avoid resorting to empirical treatments that contribute to the development of antimicrobial resistance.

Countries:
Spain
Regions:
Valencian Community
Centers:
UNIVERSITAT POLITECNICA DE VALENCIA, INST DE INVESTIG SANITARIA FUNDACION PARA LA INVESTIGACION HOSPITAL LA FE
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

ADVANTAGES - Rapid detection: The system detects Pseudomonas aeruginosa in less than 30 minutes. - Prevention of antimicrobial resistance by enabling early detection. BUSINESS APPL. - Healthcare Diagnostics. - Infectious Disease Management.

Comments

Other related patents

Health

METHOD FOR DIAGNOSING CELIAC DISEASE BASED ON THE LEVEL OF EXPRESSION OF THE UBE2L3 GENE

Countries
Spain
Know more
Health

POLYMERS FOR GENE THERAPY

Countries
Spain
Know more
Health
Chemicals
Other
Energy

PROAN Process Analyzer

Countries
Spain
Know more
Get back to patents directory